Clinical Probiotic Strains · Fermented/Probiotic
Bifidobacterium adolescentis ATCC 15703
Preliminary EvidenceCompound
Hermetica Superfood Encyclopedia
Bifidobacterium adolescentis ATCC 15703 is a well-characterized probiotic strain that produces β-glucosidase enzymes (BaBgl1A, BaBgl3A, BaBgl3B) to break down complex carbohydrates and may modulate immune responses via Th2 pathway suppression. Research suggests it can reduce airway eosinophil infiltration in allergic inflammation models and supports gut carbohydrate metabolism through multifunctional hydrolase activity.
Bifidobacterium adolescentis ATCC 15703 is a type strain of anaerobic, Gram-positive, rod-shaped bacterium originally isolated from the intestine of an adult human. It serves as the reference strain (also known as E194a or DSM 20083) for this species commonly found in the gastrointestinal tracts of humans and primates. The strain is maintained and distributed by culture collections like ATCC as a live microbial culture for research purposes.
Evidence for Bifidobacterium adolescentis ATCC 15703 is limited to preclinical studies with no human clinical trials, RCTs, or meta-analyses identified. The primary study (PMID: 29633635) examined prophylactic oral treatment in a mouse model of allergic asthma, showing strain- and host genetics-dependent effects on airway inflammation. Additional research focused on in vitro characterization of β-glucosidase enzymes and adhesion properties.
No clinically studied dosage ranges are available from human trials for Bifidobacterium adolescentis ATCC 15703. In the mouse asthma model, oral preventive treatment was used, but specific doses, forms, or CFU counts were not detailed. The strain is typically handled as a live culture in research settings without specified standardization. Consult a healthcare provider before starting any new supplement.
As a probiotic bacterial strain, Bifidobacterium adolescentis ATCC 15703 does not contribute meaningful macronutrient or micronutrient content in the conventional dietary sense. Its primary bioactive contributions are functional and metabolic in nature. Key bioactive compounds and metabolic outputs include: Short-chain fatty acids (SCFAs), predominantly acetate and lactate, produced as fermentation end-products of dietary carbohydrates — acetate production is a hallmark of Bifidobacterium metabolism and contributes to colonic acidification and epithelial energy supply. The strain produces functional β-glucosidase enzymes (BaBgl1A, BaBgl3A, BaBgl3B) that hydrolyze glycosidic bonds in dietary oligosaccharides and glycosides, potentially liberating bioavailable aglycones (e.g., flavonoid aglycones from plant glycosides), thereby improving phytonutrient bioavailability from the diet. B. adolescentis species are known contributors to folate (vitamin B9) biosynthesis in the gut environment, though strain-specific quantification for ATCC 15703 is not precisely established in available literature. The strain's genome encodes carbohydrate-active enzymes (CAZymes) enabling fermentation of prebiotics such as fructooligosaccharides (FOS) and inulin. Protein content of the bacterial cell mass itself is approximately 50–60% of dry cell weight (consistent with Bifidobacterium genus norms), but this is not nutritionally relevant at typical probiotic doses (10^8–10^10 CFU). No significant mineral, fat-soluble vitamin, or lipid contributions have been specifically characterized for this strain.
B. adolescentis ATCC 15703 expresses three distinct β-glucosidases (BaBgl1A, BaBgl3A, BaBgl3B) that hydrolyze β-glucosidic linkages in dietary oligosaccharides and cellulosic substrates, facilitating short-chain fatty acid (SCFA) production in the colon. In allergic inflammation models, this strain appears to downregulate Th2-skewed immune responses, reducing IL-4, IL-5, and IL-13 cytokine signaling that drives eosinophil recruitment into airway tissue. Additionally, colonization may promote regulatory T-cell activity and modulate intestinal epithelial barrier integrity through SCFA-mediated histone deacetylase inhibition.
Preclinical evidence from a 2018 mouse model of ovalbumin-induced allergic asthma (PMID: 29633635) demonstrated that oral administration of B. adolescentis ATCC 15703 reduced eosinophil influx into bronchoalveolar lavage fluid, though the magnitude of effect varied significantly depending on host genetic background, indicating gene-microbiome interactions are relevant. Enzymatic studies have confirmed in vitro that the three β-glucosidase enzymes (BaBgl1A, BaBgl3A, BaBgl3B) exhibit broad substrate specificity and thermostability, supporting their functional role in carbohydrate digestion. No large-scale randomized controlled trials in humans have been conducted specifically on this strain, meaning the current evidence base is preliminary and largely mechanistic or animal-derived. Human clinical translation remains unestablished, and extrapolation from mouse data should be made cautiously.
B. adolescentis ATCC 15703, like most Bifidobacterium strains, is generally considered safe for healthy adults and is classified as GRAS (Generally Recognized As Safe) by regulatory precedent for the broader species. Immunocompromised individuals, those with central venous catheters, or patients with active inflammatory bowel disease should consult a physician before use, as rare cases of bacteremia have been reported with probiotic organisms in vulnerable populations. No specific drug interactions have been formally characterized for this strain, though concurrent use with broad-spectrum antibiotics would be expected to reduce its viability and efficacy. Safety data during pregnancy and lactation specific to this strain are absent; general probiotic use is considered low-risk in pregnancy but should be discussed with a healthcare provider.
